Biocon Chief Extols Moderna’s Success To Spur ‘Risk-Averse’ VCs in India

Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.

Kiran Mazumdar Shaw
Biocon Chief Kiran Mazumdar-Shaw • Source: Alamy

Kiran Mazumdar-Shaw is known for her straight talk and Biocon, Ltd.’s billionaire chairperson minced no words at a recent conference when she called out venture capital firms for having “failed” the biotech sector in India.

In a fireside chat at a summit organized by IIM (Ahmedabad) Healthcare ASIG (Alumni Special Interest Groups) and TiE Mumbai, Mazumdar-Shaw, who considers herself an “accidental entrepreneur”, said that the...

More from Business

More from Scrip